Table 2.
Intranasal therapy of EAMG by AChR fragments
| Treatment | Clinical score, no./total*
|
Healthy rats, % | AChoR content†
|
|||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | fmol/mg protein | % | ||
| Control vehicle (ovalbumin; day +3 to +14) | 0/10 | 2/10 | 4/10 | 3/10 | 1/10 | 0 | 11.2 ± 1.3 | 32 |
| Day −5 to +6 | 5/6 | 1/6 | 83 | 21.7 ± 5.8 | 63 | |||
| Day +3 to +14 | 2/5 | 2/5 | 1/5 | 40 | 27.3 ± 10.2 | 79 | ||
| Day +7 to +18 | 3/10 | 3/10 | 3/10 | 1/10 | 30 | 27.4 ± 8.5 | 79 | |
*
Evaluated 8 weeks after the induction of EAMG.
†
Muscle AChoR content in normal age matched rats was 34.2 ± 8.5 fmols/mg protein and was referred to as the 100% value for this experiment.